Digest Network Come funziona
Network
/
Società
Im
Non verificato

Immunome, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

66 comunicati stampa

Guarda tutti i comunicati
20/07/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
08/07/2026
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
07/07/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Mercato azionario
Finanza
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
11/06/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
04/06/2026
Mercato azionario
Finanza
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
30/05/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Web e Social Network
Eventi
Biotecnologia
Oncologia
Comunicazione
Sanità
Salute
Igiene alimentare
Medicina - Varie
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Oncologia
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0
29/04/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Fonte
Immunome, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0